Episode Details:

Our Guest: Sharon Rogers, CEO at AmyriAD Therapeutics

What you’ll get out of this episode:

  • Rogers’ background
  • An overview of AmyriAD Therapeutics
  • The company’s lead compound, AD101
  • Their clinical trials & what they’re showing
  • Launching a Phase 3 Study
  • What’s next?

Watch and listen here: #345 – Sharon Rogers, CEO at AmyriAD Therapeutics – Slice of Healthcare